Tao Yu, Aditi Dey Poonam, Amy Halbing, Shengwei Zhang, Yingmiao Liu, Zheng Li, William Marx, Andrew B. Nixon and Qingshan Wei

Tao Yu received his PhD in Analytical Chemistry from Nanjing University, China. After completing postdoctoral training at North Carolina State University, he is now an R&D Engineer at SMIC, focusing on the research of plasma etching for chips.

Aditi Dey Poonam is currently a PhD student in Wei’s group at North Carolina State University. Her research interests include point-of-care molecular assays, microfluidics, and lab-on-a-chip devices.

Amy Halbing, previously an undergraduate researcher in Wei’s group, is now a PhD student at Charité Universitätsmedizin Berlin, studying the relationship between childhood maltreatment, diurnal cortisol patterns in pregnancy, and immune cell profiles in mid-gestation.

Shengwei Zhang completed his PhD in Chemical and Biomolecular Engineering at North Carolina State University. He has research interests span from nanomaterials synthesis, characterization, to 3D printing.

Yingmiao Liu is a Senior Research Associate at Duke Phase I Biomarker Laboratory. With more than 30 years of experience in RNA and protein biomarker research, Dr. Liu is dedicated to searching for predictive markers that enable precision medicine across diverse cancer patient populations.

Zheng Li received a PhD in Chemistry from the University of Illinois at Urbana-Champaign and finished postdoctoral training at North Carolina State University. He is currently a full professor at Jinan University, China, focusing on developing wearable sensors, noninvasive diagnostics, and nano-enabled technologies for human health, agriculture, and environmental monitoring.

William Marx, previously an undergraduate researcher in Wei’s group, is now an Associate Specialist at Merck.

Andrew B. Nixon is a Professor of Medicine and Director of the Phase I Biomarker Laboratory at Duke University. He is a nationally recognized expert regarding the development of biomarkers, bringing extensive experience in coordinating multi-investigator and multi-center correlative analyses at Duke and the NCI-NCTN network. Dr. Nixon serves in various leadership roles within the NCI, working with diverse multi-disciplinary teams focused on improving cancer patient outcomes through biomarker science.

Qingshan Wei is an Associate Professor of Chemical and Biomolecular Engineering and also the lead investigator for this work, who leads a research team at NC State, focusing on developing point-of-care diagnostic and sensing technologies for human and plants.